Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
International Urology and Nephrology
Published in: International Urology and Nephrology 8/2023

10-06-2023 | Sufentanil | Urology - Original Paper

Sufentanil inhibits Pin1 to attenuate renal tubular epithelial cell ischemia–reperfusion injury by activating the PI3K/AKT/FOXO1 pathway

Authors: Chunhui Liu, Qingdong Wang, Li Niu

Published in: International Urology and Nephrology | Issue 8/2023

Login to get access

Abstract

Background

Renal ischemia–reperfusion injury (RIRI) has become a great concern in clinical practice with high morbidity and mortality rates. Sufentanil has protective effects on IRI-induced organ injury. Herein, the effects of sufentanil on RIRI were investigated.

Methods

RIRI cell model was established by hypoxia/reperfusion (H/R) stimulation. The mRNA and protein expressions were assessed using qRT-PCR and western blot. TMCK-1 cell viability and apoptosis were assessed using MTT assay and flow cytometry, respectively. The mitochondrial membrane potential and ROS level were detected by JC-1 mitochondrial membrane potential fluorescent probe and DCFH-DA fluorescent probe, respectively. LDH, SOD, CAT, GSH and MDA levels were determined by the kits. The interaction between FOXO1 and Pin1 promoter was analyzed using dual luciferase reporter gene and ChIP assays.

Results

Our results revealed that sufentanil treatment attenuated H/R-induced cell apoptosis, mitochondrial membrane potential (MMP) dysfunction, oxidative stress, inflammation and activated PI3K/AKT/FOXO1 associated proteins, while these effects were reversed by PI3K inhibitor, suggesting that sufentanil attenuated RIRI via activating the PI3K/AKT/FOXO1 signaling pathway. We subsequently found that FOXO1 transcriptionally activated Pin1 in TCMK-1 cells. Pin1 inhibition ameliorated H/R-induced TCMK-1 cell apoptosis, oxidative stress and inflammation. In addition, as expected, the biological effects of sufentanil on H/R-treated TMCK-1 cells were abrogated by Pin1 overexpression.

Conclusion

Sufentanil reduced Pin1 expression through activation of the PI3K/AKT/FOXO1 signaling to suppress cell apoptosis, oxidative stress and inflammation in renal tubular epithelial cells during RIRI development.
Appendix
Available only for authorised users
Literature
1.
2.
Bonventre JV, Weinberg JM (2003) Recent advances in the pathophysiology of ischemic acute renal failure. J Am Soc Nephrol 14(8):2199–2210PubMedCrossRef
3.
Devarajan P (2006) Update on mechanisms of ischemic acute kidney injury. J Am Soc Nephrol 17(6):1503–1520PubMedCrossRef
4.
Smith SF, Hosgood SA, Nicholson ML (2019) Ischemia-reperfusion injury in renal transplantation: 3 key signaling pathways in tubular epithelial cells. Kidney Int 95(1):50–56PubMedCrossRef
5.
Dong Y, Yin J, Chen T, Wen J, Zhang Q, Li X et al (2021) Dl-3-n-butylphthalide pretreatment attenuates renal ischemia/reperfusion injury. Biochem Biophys Res Commun 557:166–173PubMedCrossRef
6.
Case J, Khan S, Khalid R, Khan A (2013) Epidemiology of acute kidney injury in the intensive care unit. Crit Care Res Prac 2013:479730
7.
Hosszu A, Fekete A, Szabo AJ (2020) Sex differences in renal ischemia-reperfusion injury. Am J Physiol Renal Physiol 319(2):F149–F154PubMedCrossRef
8.
Zhang J, Han C, Dai H, Hou J, Dong Y, Cui X et al (2016) Hypoxia-Inducible factor-2α limits natural killer T cell cytotoxicity in renal ischemia/reperfusion injury. J Am Soc Nephrol 27(1):92–106PubMedCrossRef
9.
Rabb H, Griffin MD, McKay DB, Swaminathan S, Pickkers P, Rosner MH et al (2016) Inflammation in AKI: current understanding, key questions, and knowledge gaps. J Am Soc Nephrol 27(2):371–379PubMedCrossRef
10.
11.
Lango R, Mroziński P (2010) Clinical importance of anaesthetic preconditioning. Anestezjol Intens Ter 42(4):206–212PubMed
12.
Swyers T, Redford D, Larson DF (2014) Volatile anesthetic-induced preconditioning. Perfusion 29(1):10–15PubMedCrossRef
13.
Zhao L, Li Y (2020) Application of dexmedetomidine combined with sufentanil in colon cancer resection and its effect on immune and coagulation function of patients. Oncol Lett 20(2):1288–1294PubMedPubMedCentralCrossRef
14.
Zhou H, Zhu ZH, Liu Y, Liu YY (2020) Effects of midazolam combined with sufentanil on injury and expression of HMGB1 and NF-κB in rats with pancreatitis. Eur Rev Med Pharmacol Sci 24(4):2102–2109PubMed
15.
Wang XH, Zeng JF, Lin C, Chen SB (2015) Effects of morphine and sufentanil preconditioning against myocardial ischemic-reperfusion injury in rabbits. Int J Clin Exp Med 8(9):15692–15699PubMedPubMedCentral
16.
Zuo Y, Cheng X, Gu E, Liu X, Zhang L, Cao Y (2014) Effect of aortic root infusion of Sufentanil on ischemia-reperfusion injury in patients undergoing mitral valve replacement. J Cardiothorac Vasc Anesth 28(6):1474–1478PubMedCrossRef
17.
Lian YH, Fang J, Zhou HD, Jiang HF, Xie KJ (2019) Sufentanil preconditioning protects against hepatic ischemia-reperfusion injury by suppressing inflammation. Med Sci Monit 25:2265–2273PubMedPubMedCentralCrossRef
18.
Wu Q, Shang Y, Bai Y, Wu Y, Wang H, Shen T (2021) Sufentanil preconditioning protects against myocardial ischemia/reperfusion injury via miR-125a/DRAM2 axis. Cell cycle (Georgetown, Tex) 20(4):383–391PubMedCrossRef
19.
Chen Y, Li Z, Li H, Su W, Xie Y, Pan Y et al (2020) Apremilast regulates the Teff/Treg balance to ameliorate uveitis via PI3K/AKT/FoxO1 signaling pathway. Front Immunol 11:581673PubMedPubMedCentralCrossRef
20.
21.
Villegas SN, Gombos R, García-López L, Gutiérrez-Pérez I, García-Castillo J, Vallejo DM et al (2018) PI3K/Akt cooperates with oncogenic notch by inducing nitric oxide-dependent inflammation. Cell Rep 22(10):2541–2549PubMedCrossRef
22.
Xu S, Wang J, Zhong J, Shao M, Jiang J, Song J et al (2021) CD73 alleviates GSDMD-mediated microglia pyroptosis in spinal cord injury through PI3K/AKT/Foxo1 signaling. Clin Transl Med 11(1):e269PubMedCrossRef
23.
Link W (2019) Introduction to FOXO biology. Methods Mol Biol (Clifton, NJ) 1890:1–9CrossRef
24.
Chen E, Chen C, Niu Z, Gan L, Wang Q, Li M et al (2020) Poly(I:C) preconditioning protects the heart against myocardial ischemia/reperfusion injury through TLR3/PI3K/Akt-dependent pathway. Signal Transduct Target Ther 5(1):216PubMedPubMedCentralCrossRef
25.
Wang D, Wang Y, Zou X, Shi Y, Liu Q, Huyan T et al (2020) FOXO1 inhibition prevents renal ischemia-reperfusion injury via cAMP-response element binding protein/PPAR-γ coactivator-1α-mediated mitochondrial biogenesis. Br J Pharmacol 177(2):432–448PubMedCrossRef
26.
Wang L, Ge C, Zhang X (2022) Sufentanil ameliorates oxygen-glucose deprivation/reoxygenation-induced endothelial barrier dysfunction in HCMECs via the PI3K/Akt signaling pathway. Exp Ther Med 24(1):437PubMedPubMedCentralCrossRef
27.
Lu KP, Zhou XZ (2007) The prolyl isomerase PIN1: a pivotal new twist in phosphorylation signalling and disease. Nat Rev Mol Cell Biol 8(11):904–916PubMedCrossRef
28.
Balaganapathy P, Baik SH, Mallilankaraman K, Sobey CG, Jo DG, Arumugam TV (2018) Interplay between Notch and p53 promotes neuronal cell death in ischemic stroke. J Cereb Blood Flow Metab 38(10):1781–1795PubMedCrossRef
29.
Zhao X, Wang D, Wan S, Liu X, Wang W, Wang L (2021) The suppression of Pin1-alleviated oxidative stress through the p38 MAPK pathway in ischemia- and reperfusion-induced acute kidney injury. Oxid Med Cell Longev 2021:1313847PubMedPubMedCentralCrossRef
30.
Chang HM, Berde CB, Holz GG, Steward GF, Kream RM (1989) Sufentanil, morphine, met-enkephalin, and kappa-agonist (U-50488H) inhibit substance P release from primary sensory neurons: a model for presynaptic spinal opioid actions. Anesthesiology 70(4):672–677PubMedCrossRef
31.
Feng B, Dong Z, Wang Y, Yan G, Yang E, Cheng H et al (2021) Li-ESWT treatment reduces inflammation, oxidative stress, and pain via the PI3K/AKT/FOXO1 pathway in autoimmune prostatitis rat models. Andrology 9(5):1593–1602PubMedCrossRef
32.
Ahonen J, Olkkola KT, Hynynen M, Seppälä T, Ikävalko H, Remmerie B et al (2000) Comparison of alfentanil, fentanyl and sufentanil for total intravenous anaesthesia with propofol in patients undergoing coronary artery bypass surgery. Br J Anaesth 85(4):533–540PubMedCrossRef
33.
34.
Guerra-Mora JR, Perales-Caldera E, Aguilar-León D, Nava-Sanchez C, Díaz-Cruz A, Díaz-Martínez NE et al (2017) Effects of sildenafil and tadalafil on edema and reactive oxygen species production in an experimental model of lung ischemia-reperfusion injury. Transpl Proc 49(6):1461–1466CrossRef
35.
Ishimoto Y, Tanaka T, Yoshida Y, Inagi R (2018) Physiological and pathophysiological role of reactive oxygen species and reactive nitrogen species in the kidney. Clin Exp Pharmacol Physiol 45(11):1097–1105PubMedPubMedCentralCrossRef
36.
Shan Y, Chen D, Hu B, Xu G, Li W, Jin Y et al (2021) Allicin ameliorates renal ischemia/reperfusion injury via inhibition of oxidative stress and inflammation in rats. Biomed Pharmacother Biomed Pharmacother 142:112077PubMedCrossRef
37.
Theofilatos D, Fotakis P, Valanti E, Sanoudou D, Zannis V, Kardassis D (2018) HDL-apoA-I induces the expression of angiopoietin like 4 (ANGPTL4) in endothelial cells via a PI3K/AKT/FOXO1 signaling pathway. Metab Clin Exp 87:36–47PubMedCrossRef
38.
He F, Zhang N, Lv Y, Sun W, Chen H (2019) Low-dose lipopolysaccharide inhibits neuronal apoptosis induced by cerebral ischemia/reperfusion injury via the PI3K/Akt/FoxO1 signaling pathway in rats. Mol Med Rep 19(3):1443–1452PubMedPubMedCentral
39.
Zhu J, Xue JC, Law PY, Claude PA, Luo LY, Yin J et al (1996) The region in the mu opioid receptor conferring selectivity for sufentanil over the delta receptor is different from that over the kappa receptor. FEBS Lett 384(2):198–202PubMedCrossRef
40.
Zou S, Sun H, Peng Y, Liang C, Zheng C, Wang L et al (2023) Mu-opioid receptor alleviated ferroptosis in hepatic ischemia-reperfusion injury via the HIF-1α/KCNQ1OT1 axis. Am J Physiol Cell Physiol 324(4):C927–C940PubMedCrossRef
41.
Ji S, Wang L (2019) μ-Opioid receptor signalling via PI3K/Akt pathway ameliorates lipopolysaccharide-induced acute respiratory distress syndrome. Exp Physiol 104(10):1555–1561PubMedCrossRef
42.
Kuboki S, Sakai N, Clarke C, Schuster R, Blanchard J, Edwards MJ et al (2009) The peptidyl-prolyl isomerase, Pin1, facilitates NF-kappaB binding in hepatocytes and protects against hepatic ischemia/reperfusion injury. J Hepatol 51(2):296–306PubMedPubMedCentralCrossRef
43.
Chuang HH, Zhen YY, Tsai YC, Chuang CH, Huang MS, Hsiao M et al (2021) Targeting Pin1 for modulation of cell motility and cancer therapy. Biomedicines 9(4):359PubMedPubMedCentralCrossRef
44.
Penela P, Inserte J, Ramos P, Rodriguez-Sinovas A, Garcia-Dorado D, Mayor F Jr (2019) Degradation of GRK2 and AKT is an early and detrimental event in myocardial ischemia/reperfusion. EBioMedicine 48:605–618PubMedPubMedCentralCrossRef
45.
Baik SH, Fane M, Park JH, Cheng YL, Yang-Wei Fann D, Yun UJ et al (2015) Pin1 promotes neuronal death in stroke by stabilizing Notch intracellular domain. Ann Neurol 77(3):504–516PubMedCrossRef
Metadata
Title
Sufentanil inhibits Pin1 to attenuate renal tubular epithelial cell ischemia–reperfusion injury by activating the PI3K/AKT/FOXO1 pathway
Authors
Chunhui Liu
Qingdong Wang
Li Niu
Publication date
10-06-2023
Publisher
Springer Netherlands
Keyword
Sufentanil
Published in
International Urology and Nephrology / Issue 8/2023
Print ISSN: 0301-1623
Electronic ISSN: 1573-2584
DOI
https://doi.org/10.1007/s11255-023-03651-9

Other articles of this Issue 8/2023

International Urology and Nephrology 8/2023 Go to the issue

Nephrology - Review

NETosis and kidney disease: what do we know?

Nephrology - Original Paper

Associations of systolic blood pressure and in-hospital mortality in critically ill patients with acute kidney injury

Nephrology - Original Paper

Association of urinary liver-type fatty acid-binding protein with renal functions and antihyperglycemic drug use in type 2 diabetic nephropathy patients

Urology - Original Paper

A novel less-traumatic needle for kidney puncture: first clinical experience

Urology - Original Paper

Exploring the characteristics of gut microbiome in patients of Southern Fujian with hypocitraturia urolithiasis and constructing clinical diagnostic models

Urology - Original Paper

Endocrine immune-related adverse events in patients with metastatic renal and urothelial cancer treated with immune checkpoint-inhibitors
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits